|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2024
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; Visco, Carlo; Meerten, Tom van; Wirths, Stefan; Zinzani, Pier Luigi; Novak, Urban; Herhaus, Peter; Benedetti, Fabio; Sonnevi, Kristina; Hanoun, Christine; Hänel, Matthias; Dierlamm, Judith; Pott, Christiane; Klapper, Wolfram; Gözel, Döndü; Schmidt, Christian; Unterhalt, Michael; Ladetto, Marco und Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389
(2024):
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
In: Lancet [Forthcoming]
ORCID: https://orcid.org/0000-0002-0749-1389
(2024):
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
In: Lancet [Forthcoming]
2023
Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Delfau-Larue, Marie-Hélène ORCID: https://orcid.org/0000-0002-8010-2343; Macintyre, Elizabeth; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Stilgenbauer, Stephan; Vehling-Kaiser, Ursula; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Tilly, Hervé ORCID: https://orcid.org/0000-0001-7022-5246; Wirths, Stefan ORCID: https://orcid.org/0000-0003-2494-9862; Feugier, Pierre; Hübel, Kai; Schmidt, Christian; Ribrag, Vincent; Kluin-Nelemans, Johanna C. ORCID: https://orcid.org/0000-0003-2617-9427; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340
(2023):
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma. Results From the European Mantle Cell Lymphoma Elderly Trial.
In: Journal of Clinical Oncology, Bd. 42, Nr. 5: S. 538-549
ORCID: https://orcid.org/0000-0002-0749-1389; Delfau-Larue, Marie-Hélène ORCID: https://orcid.org/0000-0002-8010-2343; Macintyre, Elizabeth; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Stilgenbauer, Stephan; Vehling-Kaiser, Ursula; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Tilly, Hervé ORCID: https://orcid.org/0000-0001-7022-5246; Wirths, Stefan ORCID: https://orcid.org/0000-0003-2494-9862; Feugier, Pierre; Hübel, Kai; Schmidt, Christian; Ribrag, Vincent; Kluin-Nelemans, Johanna C. ORCID: https://orcid.org/0000-0003-2617-9427; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340
(2023):
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma. Results From the European Mantle Cell Lymphoma Elderly Trial.
In: Journal of Clinical Oncology, Bd. 42, Nr. 5: S. 538-549